We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Issues Critical Path Report Highlighting Research for Generics
U.S. FDA Issues Critical Path Report Highlighting Research for Generics
May 15, 2007
The U.S. Food and Drug Administration (FDA) announced the availability of the “Critical Path Opportunities for Generic Drugs” report, detailing many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor